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Abstract
Enzyme supplementation with a β-mannanase to degrade β-mannan fibers present in the diet has been shown to
restore and improve performance in swine. The current study was conducted on a farm which had historical
episodes of post-weaning diarrhea. In total, 896 newly weaned piglets were enrolled in two consecutive trials. Each
trial consisted of 32 pens of 14 piglets housed in one large post-weaning compartment. Piglets at the same feeder
were randomly assigned to the two treatment groups. The study compared the performance of post-weaned
piglets fed either a commercial 3-phase nursery diet (Control) or an adapted diet supplemented with a β-
mannanase (Hemicell HT; Elanco) (Enzyme), with some of the more expensive proteins replaced by soy bean meal
in phase 1 and 2, and net energy (NE) content reduced by 65 kcal/kg in phase 3. All data analyses were performed
using R version 3.6.3 (R Core Team, 2020). All tests were performed at the 5% level of significance. When multiple
testing was involved, the nominal 5% Familywise Error Rate (FWER) was used. The study showed similar
performance on the alternative diet with β-mannanase and the common commercial diets (P > 0.05). However, the
Enzyme treated group had a significantly better general clinical score. Moreover, the number of individual
treatments was a factor exp(0.69441) or 2 (CI 95% [1.46; 2.74]) higher (P < 0.001) in the Control group as compared
to the Enzyme treated group. The number of treated animals was a factor exp(0.62861) or 1.87 (CI 95% [1.43; 2.53])
higher (P < 0.001) and the number of pigs with a repeated treatment was a factor exp(0.9293) or 2.53 (CI 95% [1.26;
5.09]) higher (P = 0.009) in the Control group as compared to the Enzyme treated group. In total, 7 (1.56%) piglets
died in the Control group, whereas only 2 (0.45%) piglets died in the Enzyme treated group. The hazard ratio for
mortality in the Control group relative to the Enzyme treated group was and estimated as 1.74 (CI 95% [0.51; 5.96]).
Thus, the Control group had a non-significantly (P = 0.375) increased mortality. In conclusion, the results suggest
that the use of an exogenous heat-tolerant β-mannanase allowed reduced levels of expensive protein sources to
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be used in the first two diets fed post-weaning, and 65 kcal/kg lower net energy content to be used in the third
diet without adverse effects on intestinal health or overall performance. In fact, the occurrence of PWD and number
of individual treatments during the post-weaning period were significantly reduced on the β-mannanase
supplemented diets.
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Introduction
Piglet post-weaning diets are by far the most expensive
diets in the swine industry, mainly due to the need to in-
clude highly digestible feed ingredients to reduce post-
weaning diarrhea (PWD) and to optimize growth per-
formance. Globally, soybean meal (SBM) is by far the
most widely used protein source in animal feeds, ac-
counting for nearly 69% of all protein sources [1]. Soy-
bean meals’ widespread use is motivated by its high
content of digestible protein, good amino acid balance
and relatively low cost. It would therefore be economic-
ally advantageous, if some of the expensive protein
sources that are generally considered necessary in diets
for newly weaned piglets could be substituted with SBM.
Unfortunately, SBM contains 17 to 27% non-starch poly-
saccharides (NSP), which are indigestible for monogas-
tric animals [2], together with several antinutritive
factors, such as trypsin inhibitors, antigenic factors, and
phytate [1]. β-Mannan is another antinutritive factor
found in SBM and many other common feed ingredients
[3], which has received increasing attention in recent
years. β-Mannans are linear polysaccharides composed
of repeating units of β-1,4-mannose and α-1,6-galactose
and/or glucose units attached to the β-mannan back-
bone [4, 5]. They are considered unsuitable for young
piglets due to their antinutritive properties, mainly due
to the stimulation of the innate immune response. The
innate immune cells identify pathogens using distinct
molecules, called pathogen associated molecular patterns
(PAMP), expressed on the pathogen surface [6]. Binding
of PAMP to pathogen recognition receptors (PRR)
present on innate immune cells, result in the release of
innate defense molecules such as reactive oxygen and ni-
trogen species, bacteriolytic enzymes, antimicrobial pep-
tides and complement proteins [7]. These PAMP
include complex polysaccharides such as β-mannan [6].
Therefore, β-mannans from feed can create a false signal
about the presence of pathogens in the gut, that elicits
an unwarranted immune activation [8, 9], which is also
known as a feed-induced immune response (FIIR [10];).
This recognition mistake leads to a futile immune re-
sponse that causes energy and nutrients to be wasted
[4]. Hydrolysis of these β-mannans through inclusion of
exogenous β-mannanase enzymes can reduce and poten-
tially eliminate their ability to induce FIIR.
In poultry, the inclusion of dietary β-mannanase has
been shown to improve daily gain and feed efficiency,
while decreasing digesta viscosity [11], and to upregulate
a broad range of metabolic functions related to diges-
tion, metabolism and immunity [10]. Moreover, the
beneficial effects of β-mannanase addition in chickens,
challenged with Eimeria sp. and Clostridium perfringens,
were observed with improved performance and reduced
lesion scores in disease-challenged animals [12].
Supplementation of β-mannanase to low- and high-
mannan diets has the potential to improve the perform-
ance of growing pigs [13]. Moreover, palm kernel meal
(PKM) or copra meal may partially replace corn and
SBM without reducing pig performance if β-mannanase
is supplemented to the diet [13, 14]. The improved over-
all pig performance following supplementation of β-
mannanase to corn-SBM-PKM diets might be due to in-
creased adjusted ileal digestibility of different amino
acids [15–17]. Others concluded that β-mannanase im-
proved growth performance in both weanling and
growing-finishing pigs on corn-SBM diets [18–20] with
minimal effects on nutrient digestibility [19].
Additionally, β-mannanase supplementation to corn-
SBM diets reduced the population of fecal coliforms and
tended to reduce the NH3 concentration of fecal slurry
after 24 h fermentation [21]. The reduction of fecal coli-
forms might impact the environmental infection pres-
sure of coliforms, related to clinical problems of PWD.
Therefore, inclusion of β-mannanase in corn-SBM diets
of weanling piglets might be beneficial to reduce gut
health problems in these younger animals [21]. Another
study demonstrated in vivo anti-inflammatory activity of
mannanase-hydrolyzed copra meal in a porcine colitis
model, with decreased expression of mRNA for ileal IL-
1β, IL-6, IL-17 and TNF-α [22]. Indeed, LPS immune
stimulation increased energy partitioning to the immune
system by 23%, which impacted lipid deposition and
weight gain in challenged young weaned piglets [23]. In-
nate immune activation is accompanied by down-
regulation of anabolic functions [24], which translates
into a reduced performance capacity. Understanding en-
ergy and nutrient partitioning in immune-stressed pig-
lets may provide more insights into the effects of FIIR
activation by β-mannans from feed.
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The objective of the current study was to evaluate the
effects of β-mannanase supplementation to nursery diets
with reduced content of expensive, high quality proteins
on performance and health of nursery piglets vaccinated
against a natural E. coli PWD infection.
Materials and methods
Description of experimental farm
The field trial was performed on a conventional farrow-
to-finish pig farm with 600 DanBred sows in Flanders
(Belgium), managed in a 4-week batch-management sys-
tem with 120 sows per production batch. The farm was
managed on all-in/all-out basis in all production phases.
This management approach improved the health status
for several respiratory pathogens [25].
Piglets (DanBred x German Piétrain) were weaned at
21 days of age and housed in a specifically equipped
post-weaning facility, where they were raised for 7 weeks
(49 days). The post-weaning facility was equipped with
32 pens of 14 piglets, allocated in 8 rows of 4 pens, sepa-
rated by 4 inspection aisles. Every two pens were
equipped with a dry feeder with a waterer on each side,
located at the pen partition, so each feeder fed 28 piglets.
The pens were equipped with fully slatted plastic floors.
Heating was provided by hot water tubes on the ceiling
near the air inlet, and ventilation was performed through
3 ventilation tubes and fresh air entered through a perfo-
rated ceiling air inlet system.
Health status and relevant vaccination schedules
The trial farm had a conventional health status, which
meant it was negative for Pseudo Rabies Virus (PRV),
Classical Swine Fever (CSF) and African Swine Fever
(ASF) and positive for Porcine Reproductive and Re-
spiratory Syndrome virus (PRRSV), Porcine Circovirus
type 2 (PCV-2), Mycoplasma hyopneumoniae (M. hyo),
atrophic rhinitis (Pasteurella multocida & Bordetella
bronchiseptica).
Sows were vaccinated with several vaccines: PRRSV
vaccination on day 60 in gestation with a live avirulent
vaccine and 6 weeks prior to parturition, PCV-2, E. coli +
Clostridium, atrophic rhinitis and Glässerella parasuis.
Additional to these standard vaccines, all gilts were vac-
cinated against M. hyo, Influenza-A Virus - Swine (IAV-
S), Parvovirus and Erysipelothrix rhusiopathiae during
their 6-week quarantine and adaptation period. Piglets
were vaccinated during the suckling period against M.
hyo (14 days), and E. coli F4/F18 (18 days) and 7 days
post-weaning (dpw) against PCV-2.
Description of clinical problems of post-weaning diarrhea
The farm had a history of post-weaning diarrhea (PWD),
recurrently diagnosed as enterotoxigenic E. coli (ETEC)
F4, which expressed enterotoxins STa, STb and LT.
Clinical signs of PWD were characterized by watery
yellowish diarrhea from 3 dpw onwards and was con-
trolled through preventive vaccination with a live, aviru-
lent E. coli F4 and F18 vaccine (Coliprotec® F4/F18;
Elanco) at 5 days pre-weaning. Since onset of immunity
by this vaccine is 7 days, the piglets were vaccinated
timely in relation to the onset of clinical signs of PWD.
Without E. coli vaccination, at least 10 days of anti-
microbial treatment would be necessary and mortality
would rise up to 4–5%, as observed in previous trials
with a non-vaccinated control group [26, 27]. The E. coli
vaccination had been administered as standard for sev-
eral years prior to the trial. The challenging F4-ETEC in-
fection pressure on this farm combined with the E. coli
F4/F18 vaccine has resulted in a stable clinical situation
related to PWD, although F4-ETEC might still be diag-
nosed post-weaning. Since label claims of the E. coli vac-
cine state a reduction in F4-ETEC and F18-ETEC
pathogen excretion following vaccination, it is not usual
to diagnose F4-ETEC following vaccination. No other
enteric pathogens were detected that might cause PWD.
Experimental design
Treatment groups and feeding regimen
Two experimental treatments were used, where the Con-
trol group received the standard diets and Enzyme
treated group received the adapted nursery diets. The in-
clusion of a negative control group with a 65 kcal/kg NE
reduction and without Enzyme supplementation was
sacrificed in order to obtain sufficient replicates for the
required power of the study. A 3-phase feeding program
with two basal diets was used, a common commercial
feeding program, and a similar, adapted program with
300 g/tonne of a heat-tolerant endo-1,4-β-mannanase
(Hemicell HT Dry; Elanco), where expensive protein
sources were partially replaced by extruded SBM in
phase 1 and fully replaced by dehulled SBM in phase 2,
and the enzyme was formulated to provide 65 kcal/kg
NE in phase 3. The enzyme was added to the mixer with
other minor ingredients during production of the diets
at the feed mill. The composition and nutrient content
of the diets are given in Tables 1 and 2. Briefly, the diets
used for the two treatments had similar nutrient content
per kg in all three phases: digestible lysine content of
12.1 g/kg in phase 1, 11.8 g/kg in phase 2, and 11.8 g/kg
in phase 3. Identical NE content of both Control and
Enzyme treated group of 2440 kcal/kg in phase 1 and
2425 kcal/kg in phase 2 were used, while in phase 3, the
NE content was 2399 kcal/kg in the Control diet and
2334 kcal/kg in Enzyme treated diet for a calculated NE
reduction of 65 kcal/kg (Table 2).
The 3-phase feeding programs was offered as follow-
ing: piglets were fed phase 1 feeds from days 1–15, phase
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2 feeds from days 16–27 and phase 3 diets from days
28–49.
Substitution of expensive protein sources and reduc-
tion of 65 kcal/kg NE resulted in a substantial reduction
of the feed costs as shown in Table 3. The reduction of
expensive protein sources in phase 1 had a substantial
impact and reduced the feed cost by € 29.00 per tonne,
whereas the substitutions in phase 2 and energy
reduction in phase 3 had a smaller impact of € 6.77 and
€ 4.45 per tonne, respectively.
Study animals
Two batches of 448 newly weaned piglets were allocated
to treatment by weight and sex. Castrated males and fe-
males were penned separately. The same number of cas-
trated male and female pigs were allocated to both
Table 1 Composition of the diets for phase 1, 2 and 3 in both Control and Enzyme treated group
Composition, % Weeks 1–2 Weeks 3–4 Weeks 5–7
Control Enzyme Control Enzyme Control Enzyme
Barley 2018, cleaned 20.0 20.0 20.0 20.0 25.0 25.1
Wheat 2018, cleaned 18.8 19.5 24,6 28.8 16.5 18.2
Soybean meal, extruded (Danex) 10.4 11.3 8.5 8.5 – –
Soybean meal 49% 2.5 2.5 10.4 12.4 18.9 18.7
Corn 5.0 5.0 15.0 10.0 15.0 15.0
Oat, rolled 5.0 5.0 – – – –
Barley, rolled 5.0 5.0 – – – –
Corn, extruded 5.0 5.0 – – – –
Wheat shorts – – 4.0 4.0 8.3 7.9
Wheat feed – – – – 5.0 5.0
Vitamin/mineral premixa 3.0 3.0 3.0 3.0 3.0 3.0
Sugar, palatine (Beneocarb) 1.0 1.0 1.0 1.0 – –
Beet pulp 1.0 1.0 1.0 1.0 1.0 1.0
Cocoa oil 0.500 0.500 0.5 0.5 – –
Soya oil – – 1.80 2.20 1.70 0.55
Animal fat – – – – 3.50 3.50
Citric acid 0.500 0.500 – – – –
Chalk 0.290 0.155 0.305 0.295 0.64 0.65
PX Cu 0.3% – 0.110 – – – –
Lysine 70% 1.055 1.245 0.940 0.960 0.750 0.755
L-Threonine 0.325 0.310 0.295 0.275 0.230 0.230
DL-Methionine 99% 0.320 0.340 0.290 0.295 0.225 0.225
L-Valine 0.219 0.296 0.119 0.124 0.035 0.035
L-Tryptophan 0.089 0.080 0.075 0.064 0.049 0.049
Base mix 20%b 20.0 – 8.0 – – –
Base mix 16%c – 16.0 – 6.4 – –
Potato protein concentrate 1.14d – 0.46d –
Forcital (extruded soya product) 1.71d 1.00 0.69d – – –
Wheat gluten 1.14d 1.14 0.46d – – –
Hemicell HT Dry – 0.030 – 0.030 – 0.030
a The vitamin/mineral premix was calculated to provide per kg complete feed:150,000 IE vit A, 2000 IE/kg vit D3, 100 IE/kg vit E, 2.0 mg/kg vit K3, 2.0 mg/kg vit B1,
6.0 mg/kg vit B2, 15.0 mg/kg Ca D-pantothenate, 2.0 mg/kg vit B6, 30.0 μg/kg vit B12, 30.0 mg/kg niacinamide, 1.0 mg/kg folic acid, 100 μg/kg biotine, 150 mg/kg
betainehydrochloride, 40 mg/kg vit C, 1.5 mg/kg potassium iodine, 0.42 mg/kg sodiumselenite, 20 mg/kg Cu-II-sulphate, 70 mg/kg Cu-II-chelate, 50 mg/kg
manganese, 105mg/kg ZnO, 100mg/kg Fe2SO4, 152 U/kg 1,3(4)-β-glucanase (Axtra XB 201), 1220 U/kg 1,4-β-xylanase (Axtra XB 201), 1500 FTU/kg 6-phytase
(Axtra PHY)
b Base mix 20%: Supplied 25% lactose, 5.71% potato protein conc., 5.71% wheat gluten, and 8.57% Forcital (extruded soya)
c Base mix 16%: As Base mix 20% without 20% protein products (potato protein concentrate, wheat gluten and Forcital)
d Provided as part of base mix 20%. Shown for comparison to the levels in the diets with Hemicell
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treatment groups. All piglets were ear tagged with indi-
vidual identification numbers. Sixteen replicate pens of
14 piglets were included per treatment in each batch for
a total of 32 replicates per treatment. The piglets at each
feeder were randomly assigned to one of both treatment
group: Control or Enzyme treated.
Performance data collection
Performance data were collected such as bodyweight at
day 1 (trial start), each feed change and day 49 (end of
trial). On days 1 through 11, piglet uniformity was evalu-
ated and described by pen. Feed allocation was assumed
to equal feed intake and recorded daily as feed bags of
25 kg were added to the feeders. Average daily weight
gain (ADWG), average daily feed intake (ADFI), and feed
conversion ratio (FCR) were calculated for each feeding
period and overall (Table 4). No adjustments for mortal-
ity and culls were performed, since mortality was below
2.0% and no culls occurred during the trial.
Mortality, scours, and veterinary treatments (with pre-
sumed diagnosis) were recorded daily (Tables 5 and 6).
Dead piglets were not submitted to necropsy.
Assessment of fecal clinical score and general clinical score
Pigs were evaluated daily and any unusual observations
were recorded, including but not limited to altered
Table 2 Calculated nutrient content of the diets for phase 1, 2 and 3 in both Control and Enzyme treated group
Nutrient content Weeks 1–2 Weeks 3–4 Weeks 5–7
Control Enzyme Control Enzyme Control Enzyme
Dry matter, g/kg 889.1 889.5 882.7 883.1 882.8 881.0
Moisture, g/kg 110.9 110.5 117.3 116.9 117.2 118.7
Crude protein, g/kg 169.9 165.5 179.1 179.0 179.6 180.0
Crude fiber, g/kg 34.2 34.3 35.6 35.9 39.5 39.5
Crude fat, g/kg 48.3 49.4 60.7 63.1 74.8 62.4
Ash, g/kg 47.1 46.0 47.4 47.6 51.0 51.0
Sugars, g/kg 67.2 61.0 53.7 52.8 40.5 40.5
Lactose, g/kg 50.0 50.0 20.0 20.0 – –
Starch, g/kg 344.9 367.0 358.0 359.7 351.7 360.9
Net energy, kcal/kg 2440 2439 2425 2426 2399 2334
Lysine, total, g/kg 13.74 13.62 13.47 13.43 12.38 12.39
Lysine, digestible, g/kg 12.10 12.10 11.81 11.82 10.80 10.81
Methionine, digestible, g/kg 5.19 5.21 4.96 4.95 4.31 4.32
Methionine+Cysteine, digestible, g/kg 7.37 7.89 7.23 7.43 6.64 6.66
Threonine, digestible, g/kg 7.60 7.64 7.43 7.44 6.82 6.82
Tryptophan, digestible, g/kg 2.42 2.42 2.36 2.36 2.16 2.16
Isoleucine, digestible, g/kg 5.09 5.08 5.43 5.68 5.40 5.40
Ca, g/kg 5.48 5.46 5.10 5.12 5.90 5.91
P, g/kg 5.21 5.25 5.60 5.63 5.91 5.90
P, digestible, g/kg 4.18 4.16 4.33 4.33 4.22 4.22
Na, g/kg 2.64 2.70 2.42 2.44 2.38 2.38
K, g/kg 7.23 7.19 8.10 8.41 8.79 8.77
Cl, g/kg 4.15 4.34 3.41 3.45 3.05 3.05
Cu, mg/kg 140 140 155 155 154 154
Zn (added), mg/kg 105 105 105 105 105 105
Table 3 Feed price (€/tonne) for both Control and Enzyme
treated diets in phase 1, 2 and 3, and reduction (expressed as
%) in feed price between Control and Enzyme treated diets
Feeding
phase







Phase 1 579.00 560.18 - 3.25
Phase 2 426.00 419.23 - 1.59
Phase 3 356.00 351.55 - 1.25
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behavior and disease. Diarrhea scores were assessed for
each pen by scoring five droppings per pen based on the
fecal clinical score (FCS) shown in Table 7 [26, 27]. The
scoring was done by the same observer on days 0 to 11
post weaning and on day 49 (end of trial). The scoring
was done by first counting all droppings with a score 2,
then score 1 and finally score 0, until a total of 5 drop-
pings had been recorded. Fecal clinical scores during the
observation period were expressed as area under the curve
(AUC0–11) and days to maximal FCS were calculated for
each pen. Simultaneously, the uniformity and appearance
of the piglets was scored by pen on a scale from 1 to 5,
where score 1 represented poor appearance (heterogen-
eity, sunken flanks, long hair coat, deep eyes, …) and score
5 represents perfect condition (homogenous, filled belly,
shiny pink skin, …). This general clinical score (GCS) was
performed every day from weaning (0 dpw) until 11 dpw
by the same observer. General clinical scores during the
observation period were expressed as area under the curve
(AUC0–11) and day to minimal GCS was calculated for
each pen. Dead piglets were recorded by date, experimen-
tal group, pen and body weight. No necropsies were
carried out.
Veterinary treatments
Individual antibiotic treatments for PWD were per-
formed as needed due to the critical state of the piglet
and according to the clinical criteria of the farm veterin-
arian. The same veterinary products, active ingredients,
formulations and dosages were used throughout the en-
tire study period. Individual antibiotics treatments were
recorded daily by date, product, dose, ID number of
treated piglets, presumed cause of treatment, and num-
ber of times the treatment was repeated. For both treat-
ment groups, the same antibiotic product and dosage
was applied for the same indication.
Table 4 Average daily weight gain (ADWG; g/piglet/d; mean ± SEM), average daily feed intake (ADFI; g/piglet/d; mean ± SEM), feed
conversion rate (FCR; kg feed/kg weight gain; mean ± SEM) in phase 1 (0–15 dpw), phase 2 (16–27 dpw), phase 3 (28–49 dpw) and
overall (0–49 dpw). Piglets in the Control group were fed a standard diet, whereas piglets in the Enzyme treated group were fed an
adapted diet with more soybean meal in phase 1 and 2, and a decreased level of 65 kcal/kg net energy in phase 3. No significant
differences (P > 0.05) between groups were observed
Production Parameter Production Phase Control Enzyme Enzyme vs. Control (%) P-value
Average Daily Weight Gain (g/piglet/d; mean ± SEM)
Phase-1 129.5 ± 3.5 117.1 ± 3.2 - 9.57 > 0.05
Phase-2 324.6 ± 17.1 303.0 ± 18.2 - 6.65 > 0.05
Phase-3 572.5 ± 48.0 566.7 ± 47.1 - 1.01 > 0.05
Overall 342.4 ± 6.6 331.9 ± 8.9 - 3.24 > 0.05
Average daily feed intake (g/piglet/d; mean ± SEM)
Phase-1 153 ± 8 143 ± 7 - 6.53 > 0.05
Phase-2 436 ± 25 409 ± 25 - 6.19 > 0.05
Phase-3 1019 ± 65 982 ± 53 - 3.63 > 0.05
Overall 536 ± 99 512 ± 95 - 4.47 > 0.05
Feed conversion ratio (kg feed/kg gain; mean ± SEM)
Phase-1 1.32 ± 0.025 1.36 ± 0.029 + 3.03 > 0.05
Phase-2 1.29 ± 0.017 1.29 ± 0.020 0.00 > 0.05
Phase-3 1.76 ± 0.073 1.79 ± 0.067 + 1.70 > 0.05
Overall 1.46 ± 0.071 1.48 ± 0.070 + 1.37 > 0.05
Table 5 Area under the curve (expressed in AUC0–11) of pen
fecal clinical score and pen general clinical score (GCS), time to
maximal FCS and GCS (expressed in dpw; mean ± SEM) for
piglets during the first 11 dpw and mortality during the entire
trial period (N piglets and %) are given. Piglets in the Control
group were fed a standard diet, whereas piglets in the Enzyme
treated group were fed an adapted diet with more soybean
meal in phase 1 and 2, and a decrease level of 65 kcal/kg net
energy in phase 3. Different superscript letters indicate
statistically significant differences (P < 0.05)
Control Enzyme
Pen FCS1 (AUC0–11) 14.40 ± 0.215
a 13.65 ± 0.134 a
Time to maximal FCS (dpw) 7.06 ± 0.100 a 6.25 ± 0.077 a
Pen GCS2 (AUC0–11) 116.0 ± 0.23
a 126.5 ± 0.14 b
Time to minimal GCS (dpw) 6.78 ± 0.108 a 6.85 ± 0.042 a
Mortality, % (N) 1.79 (8) a 0.45 (2) a
1 Pen FCS was scored daily on a score from 0 (= normal) to 2 (=
watery diarrhea)
2 GCS was scored daily on a score from 0 (= very bad) to 10 (= excellent)
AUC0–11, area under the curve 0–11 dpw, dpw Days post-weaning
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Practically, diarrhea problems were treated using a
combined product containing lincomycin-spectinomycin
(Linco-Spectin; Zoetis, Louvain-la-Neuve, Belgium; 50
mg lincomycin + 100 mg spectinomycin per ml; 1 mL
per 10 kg). Small, unthrifty piglets, piglets with leg prob-
lems and other pathologies were treated using a product
containing amoxicillin (Duphamox LA 150mg/ml; Zoe-
tis, Louvain-la-Neuve, Belgium; 150 mg amoxicillin per
ml; 1 ml per kg).
Statistical analysis
All data analyses were performed using R version 3.6.3
[28]. All tests were performed at the 5% level of signifi-
cance. When multiple testing was involved, the nominal
5% Familywise Error Rate (FWER) was used. For ADWG,
ADFI and FCR, the average values were calculated within
each trial, phase and treatment combination. These aver-
ages were considered as outcome variables and, within
each phase, analyzed with two-way ANOVA models treat-
ment and trial as factors (the latter is to be considered as a
blocking variable. The P-values (one for each phase) for
the F-test for the treatment effect were adjusted for mul-
tiple testing using the Bonferroni method. For weight, the
average values were calculated within each trial and treat-
ment combination. These averages were used as outcome
variables and analyzes with two-way ANOVA models with
trial and treatment as factors. Again, trial acted as a block-
ing factor. The F-test was used for testing the treatment
effects. For FCS and GCS, the average values were calcu-
lated for each trial, pen, treatment and dpw combination.
Subsequently, the average values of AUC0–11 for FCS and
GCS were calculated for each trial and treatment combin-
ation, and they were used as outcome variables in two-
way ANOVA models with with trial and treatment as fac-
tors. Trial acted again as a blocking factor. The F-test was
used for testing the treatment effects. The treatment effect
on the time to maximal FCS and the time to minimal
GCS was testing with the Wilcoxon rank sum statistic,
stratified according to trial, i.e. the test statistic is given by
the sum of the two trial-specific Wilcoxon rank sum sta-
tistics. The null distribution was enumerated as a permu-
tation null distribution, by (1000 times) randomly
permuting the treatment labels within the trials (thus trial
acted as a blocking factor, implying a randomization re-
striction). With this permutation null distributions, two-
sided p-values were computed. The number of treated
and the number of repeated was analyzed with a Poisson
regression model, with Pen as a blocking factor. For each
reason of treatment, the numbers in the two treatment
groups were compared with a Pearson chi-squared test.
The four P-values were adjected with the method of Bon-
ferroni. The mortality, represented as time-to-death, was
analyzed with a Cox proportional hazard model with
treatment factor variables.
Results
Piglet weight and average daily weight gain
Piglets were weaned at 21 days of age and an average
weight of 4.95 kg (± 0.06) and randomly distributed into
two treatment groups. No significant differences in
Table 6 Antimicrobial treatments during the feed trial categorized by phase and reason for treatment, including an overall total and
number of unique piglets treated and number of piglets receiving a repeated treatment with an antimicrobial during the trial.
Piglets in the Control group were fed a standard diet, whereas piglets in the Enzyme treated group were fed an adapted diet with
more soybean meal in phase 1 and 2, and a decrease level of 65 kcal/kg net energy in phase 3. Different superscript letters indicate
statistically significant differences (P < 0.05)
Treatment Control Enzyme P-value
Feeding phase Ph-1 Ph-2 Ph-3 Overall Ph-1 Ph-2 Ph-3 Overall
Diarrhea 74 0 0 74 a 33 0 0 33 a P = 0.282
Small/unthrifty 8 9 8 25 a 6 7 6 19 a P = 1.000
Leg infection 3 8 5 16 a 1 2 3 6 a P = 1.000
Meningitis 0 2 1 3 a 0 1 0 1 a P = 0.283
TOTAL 85 19 14 118 a 40 10 9 59 b P < 0.001
N pigs treated (%) 80 10 0 90 (20.1) a 40 6 2 48 (10.7) b P < 0.001
N pigs with repeated treatment (%) 5 9 14 28 (31.1) a 0 4 7 11 (22.9) b P = 0.009
Table 7 Comprehensive description of the pen fecal clinical score with its interpretation and the clinical aspect of the fecal clinical
score (adapted from Vangroenweghe et al., 2020a [26]; Vangroenweghe et al., 2020b [27])
Score Interpretation Clinical aspect
0 Normal Normal feces consistency
1 Pasty to mild Soft pasty consistency with more particles than fluid
2 Moderate to severe More fluid than particles
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piglet bodyweight were observed during the trial. How-
ever, on day 15, Control piglets were numerically heavier
than the Enzyme treated piglets, 6.77 ± 0.073 kg vs.
6.59 ± 0.071 kg, respectively, on day 27 Control and En-
zyme treated piglets weighed 11.08 kg ± 0.110 and 10.66
kg ± 0.106 respectively, and on the final weighting on
day 49 they weighed 21.68 ± 0.177 kg vs. 21.21 ± 0.194
kg, respectively (Fig. 1).
Average daily weight gain in phase 1 was 12 g/day
lower in the Enzyme treated piglets as compared to
Control. In phase 2 and 3, the daily gain on the Enzyme
treated piglets was numerically lower by 21 and 6 g/d re-
spectively. Overall, the Enzyme treated piglets gained 10
g/day less than the Control piglets. None of the treat-
ment differences in daily gain were significantly different
(Table 4).
Average daily feed intake and feed conversion rate
Similar ADFI for both treatments were observed in all
three production phases. Piglets in the Control group
tended to consume more feed than the Enzyme treated
piglets. The ADFI in each of the phases differed by 10,
27 and 37 g/day, respectively. Overall, the Control piglets
consumed 24 g/day more than the Enzyme treated pig-
lets. However, none of the differences in ADFI were
significant (P > 0.05) (Table 4).
No significant difference in feed conversion rate (FCR)
were observed. In phase 1, FCR was numerically lower
on the Control feed (1.32 ± 0.025) than on the Enzyme
treated feed (1.36 ± 0.029). In phase 2, FCR was equal
(1.29 ± 0.018) in both treatment groups, and in phase 3,
FCR on the Enzyme treated feed was again numerically
increased (1.79 ± 0.067) versus (1.76 ± 0.073). Overall,
FCR on the Enzyme treated feed was slightly, though
non-significantly higher (+ 1.37%) as compared to Con-
trol piglets (Table 4).
Pen fecal clinical score and general clinical score
Pen FCS was collected daily for each individual pen from
0 to 11 dpw. Daily average pen FCS (mean ± SEM) is
given in Fig. 2. Pen FCS, expressed as AUC0–11, was not
significantly higher (P > 0.05) in the Control group as
compared to the Enzyme treated group (Table 5). Al-
though some numerical differences in time to maximal
FCS, expressed as dpw, occurred between the treat-
ments, no significant differences in the time to maximal
FCS (P > 0.05) were observed (Table 5).
Pen GCS was collected daily for each individual pen
from 0 to 11 dpw. Daily average pen GCS (mean ± SEM)
is given in Fig. 3. Pen GCS, expressed as AUC0–11, was
significantly higher (P < 0.05) in the Enzyme treated
group as compared to the Control group (Table 3). Al-
though some numerical differences in time to minimal
GCS, expressed as dpw, occurred between both treat-
ment groups, no significant differences in the time to
minimal GCS (P > 0.05) were observed (Table 5).
Mortality
Data related to mortality are given in Table 5. In total, 7
(1.56%) piglets died in the Control group, whereas only
2 (0.45%) piglets died in the Enzyme treated group. In
summary, the hazard ratio for mortality in the Control
Fig. 1 Individual piglet weight (kg; mean ± SEM) at weaning (Start; 0 dpw), first intermediate weighing (End phase 1; 15 dpw), second
intermediate weighing (End phase 2; 27 dpw) and end of the trial (Final; 49 dpw). Piglets in the Control group were fed a standard diet, whereas
piglets in the Enzyme treated group were fed an adapted diet with more soybean meal in phase 1 and 2, and a decrease level of 65 kcal/kg net
energy in phase 3. No significant differences between groups were observed
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Fig. 2 Average fecal clinical score (mean ± SEM) from 0 to 11 dpw. Five relevant fecal droppings were scored daily per pen during the
observation period. Piglets in the Control group were fed a standard diet, whereas piglets in the Enzyme treated group were fed an adapted diet
with more soybean meal in phase 1 and 2, and a decrease level of 65 kcal/kg net energy in phase 3. No significant differences between groups
were observed
Fig. 3 Average general clinical score (mean ± SEM) from 0 to 11 dpw. Piglets in each pen were scored (0–2) daily during the observation period.
Piglets in the Control group were fed a standard diet, whereas piglets in the Enzyme treated group were fed an adapted diet with more soybean
meal in phase 1 and 2, and a decrease level of 65 kcal/kg net energy in phase 3. Significant differences (P < 0.05) were indicated with an
asterix (*)
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group relative to the Enzyme treated group was esti-
mated as 1.74 (CI 95% [0.51; 5.96]). Although the piglets
in the Control group had an increased risk of mortality,
this effect was not significant (P = 0.375) (Table 5).
Antimicrobial treatment
Antimicrobial treatment was registered per day and rea-
son of treatment. The number of treatments adminis-
tered for diarrhea tended to be higher (P > 0.05) in the
Control group (N = 74) compared to the Enzyme treated
group (N = 33) (Table 6). Moreover, all treatments
against diarrhea were administered during phase 1 (day
1–14). Unthriftyness was the second most common rea-
son for treatment, followed by leg infections (e.g. S. suis
or G. parasuis). Only a few piglets suffered from menin-
gitis due to S. suis. No significant differences (P > 0.05)
in these treatments reasons were recorded between both
treatment groups. In the Control group, the total num-
ber of antimicrobial treatments was a factor
exp(0.69441) or 2 (CI 95% [1.46; 2.74]) higher as com-
pared to the Enzyme treated group. Moreover, the total
number of individually treated piglets was a factor
exp(0.62861) or 1.87 (CI 95% [1.43; 2.53]) higher
(P < 0.001) in the Control as compared to the Enzyme
treated group. The number of piglets requiring repeated
treatment differed (P = 0.009) between both treatments
and was a factor exp(0.9293) or 2.53 (CI 95% [1.26;
5.09]) higher in the Control group as compared to the
Enzyme treated group.
Discussion
In the current study, we substituted a part of the most
expensive protein sources (potato protein concentrate,
Forcital (extruded soybean product) and wheat gluten)
with Danex® (extruded SBM) and wheat in phase 1, and
they were fully substituted with regular SBM in phase 2.
Both soya products were expected to have a similar and
relatively high β-mannan content, a known antinutritive
factor [3], which may stimulate an innate immune re-
sponse through their resemblance with PAMPs [6]. This
activation has been called FIIR (Feed Induced Immune
Response [10];) and leads to an unnecessary immune ac-
tivation, causing energy and nutrients to be wasted [4].
Therefore, 300 g/tonne of an exogenous β-mannanase
enzyme (Hemicell HT; Elanco, Greenfield, IA) was
added to hydrolyze these antinutritive β-mannans in the
trial feed. The results in phase 1 and phase 2 demon-
strated no significant differences in the measured (piglet
weight, ADFI) or calculated (ADWG, FCR) performance
parameters between treatments. Although minor numer-
ical differences were observed, the overall result con-
firmed that the addition of an exogenous β-mannanase
to adapted formulations with more challenging, β-
mannan-containing ingredients, allowed them to
perform equally to the standard post-weaned diets.
These results are in accordance with other recent studies
in low- and high-mannan diets [13].
In phase 3, the formulation of the Control and Enzyme
treated diets only differed in the inclusion of soya oil,
which was reduced from 1.70 to 0.55% to obtain a net
energy reduction of 65 kcal/kg feed. Again, in phase 3
only minor numerical performance differences were ob-
served between treatments. The overall result confirmed
that the addition of β-mannanase allowed performance
to be maintained with diets formulated with reduced
content of expensive protein sources in phase 1 and 2,
and about 3% lower dietary energy content (65 kcal/kg
net energy) in phase 3. In addition, a substantial eco-
nomic advantage of using the enzyme could be calcu-
lated. Based on the feed prices presented in Table 3 and
the actual feed intake, we obtained a 3 % reduction in
the feed cost per produced piglet. Taking into account
all costs (feed cost, veterinary treatment costs, mortality,
basic piglet market price and supplements for weight
above 20 kg), the income per produced piglet was € 0.58
higher for the Enzyme treated group. Others concluded
that β-mannanase improved growth performance in both
weanling and growing-finishing pigs on corn-SBM diets
[18–20]. A diet with a 150 kcal/kg reduction in digestible
energy supplemented with β-mannanase outperformed
in weight gain and feed efficiency [18]. Others have also
observed the energy sparing effect from supplementation
of β-mannanase. For example the supplementation to a
common nursery diet resulted in similar effects on per-
formance of a comparable diet supplemented with 2%
soya oil [19].
In poultry, beneficial effects of β-mannanase supple-
mentation on the performance of chickens challenged
with Eimeria sp. and Clostridium perfringens were ob-
served together with reduced lesion scores in disease-
challenged birds [12]. Therefore, we selected a field trial
facility with a substantial intestinal challenge related to
PWD due to E. coli, which was partly tackled using an
oral live non-pathogenic E. coli vaccine (Coliprotec® F4/
F18; Elanco, Greenfield, IA). In order to quantify intes-
tinal and general health aspects, we recorded a fecal clin-
ical score (FCS; adapted from [26, 27]) and a general
clinical score (GCS; adapted from [26, 27]) during the
most critical period post-weaning (from weaning until
11 dpw). Although some differences in kinetics could be
observed for FCS, the treatment did not differ signifi-
cantly their AUC and time to maximum FCS during the
entire period from 0 to 11 dpw. In contrast, AUC of
GCS was significantly better in the Enzyme treated
group compared to the Control group, which means that
the general condition, as scored by the farmer, was bet-
ter in the Enzyme treated group. The time to minimal
GCS, however, did not differ between treatments.
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Diseased piglets were only treated using single individual
injections and whole group treatments were not admin-
istered at any time during the trial. All individual treat-
ments were registered with date of treatment, reason for
treatment and individual piglet identification. From
Table 6, we can conclude that piglets in the Control
group received significantly more treatments for diarrhea
during phase 1 and significantly more treatments overall,
resulting in more than double the number of injections
as compared to the Enzyme treated group. From these
data, it is also obvious that more than double the num-
ber of individual piglets were injected in the Control
group and more than double (2.53) the number of pig-
lets with a repeated treatment could be registered in the
Control group as compared to the Enzyme treated
group. Combining the treatment data with the GCS re-
sults, we can conclude that overall health status in the
Enzyme treated group was significantly higher compared
to the Control group. This observation is, to our know-
ledge, the first of its kind in pigs fed a corn-SBM diet
supplemented with an exogenous β-mannanase, and
confirms the earlier data on intestinal health in poultry
following a challenge with Eimeria sp. and Clostridium
perfringens [13].
Conclusions
The current study results suggest that the use of an ex-
ogenous heat-tolerant β-mannanase allowed reduced
levels of expensive protein sources to be used in the first
two diets fed post weaning, and 65 kcal/kg lower net en-
ergy content to be used in the third without adverse ef-
fects on intestinal health or overall performance. In fact,
the occurrence of post-weaning diarrhea and number of
individual treatments during the post-weaning period
were significantly reduced on the β-mannanase supple-
mented diets.
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